Aatman Shah
MOHS-Micrographic Surgery · Plano, TXNPI 1598119687
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,214 and has fallen 78.7% since, to $472 in 2025.
Across 93 payments — averaging $58.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$734
- Sun Pharmaceutical Industries Inc.$678
- Dermavant Sciences, Inc.$657
- Arcutis Biotherapeutics, Inc.$557
- Incyte Corporation$547
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$459
- plus $2K from 18 others
What the payments were for
- Food & beverage$5,40799%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $734 |
| Sun Pharmaceutical Industries Inc. | 7 | $678 |
| Dermavant Sciences, Inc. | 6 | $657 |
| Arcutis Biotherapeutics, Inc. | 7 | $557 |
| Incyte Corporation | 13 | $547 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 5 | $459 |
| UCB, Inc. | 8 | $377 |
| E.r. Squibb & Sons, L.L.C. | 3 | $326 |
| Galderma Laboratories, L.p. | 2 | $176 |
| Boehringer Ingelheim | 2 | $167 |
| Intercept Pharmaceuticals, Inc. | 1 | $113 |
| Lilly USA, LLC | 5 | $102 |
| Amgen | 3 | $89 |
| Johnson & Johnson | 3 | $70 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Medtronic | 3 | $64 |
| Regeneron Healthcare Solutions, Inc. | 2 | $57 |
| Pfizer | 1 | $56 |
| VYNE Pharmaceuticals Inc. | 1 | $53 |
| Organon | 2 | $38 |
| EPI Health, LLC | 1 | $30 |
| Merz North America, Inc. | 1 | $24 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Novartis | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,472 in reported general payments places this provider in the 75th percentile of 109 mohs-micrographic surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 55 | $363 |
| Doxycycline Monohydrate | 18 | $118 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Plano
- Michael Kelly-SellPlano$2K
- Gunjan ModiPlano$2K
- Michael WellsPlano$2K
- Eric HollabaughPlano$1K
- Aaron FarbergRockwall$1.5M
- Suneel ChilukuriBellaire$288K
- Ryan O QuinnSan Antonio$167K
- Paul FriedmanHouston$131K
- Brent SpencerFrisco$45K
- Julie CroleyThe Woodlands$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.